Ramesh Ganju, PhD

The Ohio State University, Columbus, OH
Lung Cancer Discovery Award

Can an Enzyme Really Cause So Much Damage?

Ramesh GanjuAlmost 90% of lung cancers are non-small cell lung cancer (NSCLC). For many patients their lung cancer becomes resistant to chemotherapy. The result is less than 20% of patients live more than five years after diagnosis. Therefore, it is very important to develop new treatments. Dr. Ganju’s research is looking at whether an enzyme can interfere with a natural brain compound that he believes can block the growth and spread of lung cancer. These natural brain compounds, known as endocannabinoidsA chemical substance in the body belonging to a group resembling organic chemicals found in cannabis., attaches to receptors called CB1 and CB2 found on cells that regulate the progression and spread of NSCLC to other organs and systems. He will test the ability of endocannabinoids to block the growth and spread of cancer and whether this process is stopped by this enzyme in mice. The results of this award may lead to future research that could lead to new treatments for NSCLC to help people live longer.

"This research will hopefully lead to much needed treatments for NSCLC and could not have been possible without the support of the American Lung Association."- Ramesh Ganju, PhD

Early detection of lung cancer can increase survival rates. Call the Lung Helpline at 1-800-LUNGUSA or talk to your doctor about lung cancer screening.